MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
44.15
-2.04
-4.42%
After Hours: 44.04 -0.11 -0.26% 19:16 01/08 EST
OPEN
45.37
PREV CLOSE
46.19
HIGH
45.84
LOW
43.28
VOLUME
2.73M
TURNOVER
--
52 WEEK HIGH
49.62
52 WEEK LOW
31.90
MARKET CAP
11.84B
P/E (TTM)
18.59
1D
5D
1M
3M
1Y
5Y
1D
Has The Market Fully Reflected Exelixis (EXEL) After Its Strong Multi‑Year Share Price Run?
Simply Wall St · 13h ago
Exelixis Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 15h ago
Exelixis Price Target Raised to $52.00/Share From $49.00 by HC Wainwright & Co.
Dow Jones · 15h ago
HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $52
Benzinga · 15h ago
Exelixis price target raised to $52 from $49 at H.C. Wainwright
TipRanks · 17h ago
EXELIXIS, INC. <EXEL.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $52 FROM $49
Reuters · 18h ago
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study
NASDAQ · 18h ago
What 10 Analyst Ratings Have To Say About Exelixis
Benzinga · 19h ago
More
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.